Eupraxia reports RESOLVE trial EREFS improvements for EP-104GI in eosinophilic esophagitis

• Eupraxia Pharmaceuticals disclosed first endoscopic scoring data from ongoing Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis, with results already presented at Digestive Disease Week.
• Findings showed clearer improvement when treatment used full injection pattern, supporting broader coverage of esophageal tissue.
• Response appeared consistent across measures tied to inflammation and scarring, reinforcing dose and injection-pattern selection for later-stage testing.
• Placebo-controlled Phase 2b RESOLVE study continues to recruit at two dose levels, with top-line results expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-003003), on May 05, 2026, and is solely responsible for the information contained therein.